Research Breakthroughs in Health Care That Will Change the World: An Interview with AdventHealth Investigators

Side by side headshots of Steve Smith and Kirk Erickson
Dr. Steven Smith, senior vice president and chief scientific officer of AdventHealth (left) Kirk Erickson, Ph.D., director of translational neuroscience at the AdventHealth Research Institute (right)

There are 300+ research trials open in Central Florida at any given time, spanning a broad spectrum of studies, from how to treat diseases like cancer and Alzheimer’s to population science and molecular biology.

You don’t want to miss this episode of the Inspiring Wholeness podcast where AdventHealth’s Dr. Steven Smith and Kirk Erickson, Ph.D., share some of the biggest research breakthroughs they’ve seen, what projects are on tap, what they’re eyeing for the future and how the community can help.

“We need the community to be engaged in research. People who may not have a disease but are interested in learning more can contribute to those people who are patients and have some condition that is affecting their lives,” Erickson said. “It takes an entire village to produce the breakthroughs that are going to change the world.”

Listen now and subscribe so you never miss a new episode.

Recent News

12 items. To interact with these items, press Control-Option-Shift-Right Arrow. These items are in a slider. To advance slider forward, press Shift-Command-Right Arrow. To advance slider backward, press Shift-Command-Left Arrow.
News

AdventHealth Neuroscience Institute Among First in U.S. to Offer Phase IIa Clinical Trial of Troculeucel for Moderate Alzheimer’s Disease

While most clinical trials for Alzheimer’s disease have focused on patients with early or mild cognitive impairment, roughly 30% of those with Alzheimer’s have moderate stage disease for which there...

News

AdventHealth Translational Research Institute Selected as Clinical Site for National Study of Muscle, Mobility and Aging (SOMMA)

Under the leadership of Scientific Director and Principal Investigator Bret H. Goodpaster, PhD, the AdventHealth Translational Research Institute (TRI) is now enrolling men and women 70 years of age...

News

AdventHealth Neuroscience Institute Administers First Dose of Investigative NK Cell Therapy to Person with Alzheimer’s Disease

Under a single compassionate use Investigational New Drug (IND) authorization cleared by the U.S. Food and Drug Administration (FDA), the AdventHealth Neuroscience Institute worked with NKGen Biotech...

News

New Study Published in the New England Journal of Medicine Shows the Addition of Regional Nodal Irradiation Does Not Decrease Rate of Invasive Breast Cancer Recurrence in Patients with Negative Axillary Nodes Following Neoadjuvant Chemotherapy

Findings of the phase III, multicenter, randomized NSABP B-51-RTOG 1304 clinical trial were recently published in the New England Journal of Medicine with AdventHealth Cancer Institute’s Dr. Mamounas...

News

AdventHealth Study Exploring the Use of MR-Guided Focused Ultrasound (MRgFUS) to Disrupt the Blood-Brain Barrier for Treatment of Alzheimer’s Disease

Under the leadership of Dr. Valeria Baldivieso and Dr. Chandan Reddy, the AdventHealth Research Institute is the first and only site in Orlando offering the Exablate Blood-Brain Barrier (BBB)...